Theravance Biopharma Q1 2024: Viatris collab revenue up 39% to $14.5M; net loss narrows to $11.7M

Theravance Biopharma, Inc.

2024-Q1 EPS reported -$0.24 revenue$14,503,000

Viatris collaboration revenue of $14.5M, up 39% YoY; implied 35% share of YUPELRI net sales $19.3M, up 18%.
Net loss of $11.7M narrowed from $22.1M YoY; non-GAAP net loss from operations $4.5M vs $14.9M.
YUPELRI total net sales $55.2M (by Viatris), +18% YoY; hospital doses sold up 31%.
Cash balance $100M; R&D expenses $9.0M down from $14.6M; SG&A $16.7M down from $19.2M.
Ampreloxetine CYPRESS enrollment continues; open-label enrollment expected H2 2024; KOL event May 23.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Theravance Biopharma, Inc. reported the first quarter of 2024 results: revenue Total revenue for the first quarter of 2024 was $14.5 million, net income Net loss was $11.7 million.

Period: the first quarter of 2024
Revenue: Total revenue for the first quarter of 2024 was $14.5 million
Net income: Net loss was $11.7 million
Result: reported results

Exact text from the filing

Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results

View on SEC.gov

Browse all earnings releases →

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-060536

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.